TRVI has been the subject of a number of recent research reports. HC Wainwright upped their price objective on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback